Solexa, Inc. Form 425 January 10, 2007

Filed by Illumina, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934

> Subject Company: Solexa, Inc. Commission File No. 333-139111

TABLE OF CONTENTS

Highlights of Breakout Year in 2006 Non-GAAP O3 Financial Performance ASP for Infinium Product Family Rapid Growth in Installed Base 2006 New Products in InfiniumTM Family Recent Deal Summary **Comprehensive Suite of Gene Expression Products** Diagnostic Partnerships Creating A Powerful Life Science Franchise Solexa's Technology Solexa Technical Approach Key Technology Advantages Integration of Sequencing and Genotyping **Recent Developments and Progress** Financial Highlights of Transaction Launch of DNA Methylation Application **DNA** Methylation Methylation Product Offering Methylation Profiles of Cancer Cell Lines Biomarkers for Cancer Cell Lines Technology / Platform Synergy **Digital Code Generation** Beads Align in Groove Plate Code Detection Three Initial Kits for Research Market Distribution, Chemistry and Content Synergy The Near-Term Future of Infinium Product Line What Factors are Important in the Market? Illumina's Human 1M BeadChip Human 1M BeadChip Content Upgradeable and Compatible Products **Summary**